Active Biotech's Cancer Project ANYARA Featured in Journal of
Clinical Oncology
(Thomson Reuters ONE) - Lund, Sweden, July 28, 2009- The Journal of Clinical Oncology (DOI:10.1200/JCO.2008.20.2515) releases an article covering ActiveBiotech's (NASDAQ OMX Nordic: ACTI) cancer project ANYARA, whereANYARA was studied both as a single agent and in combination with anestablished tumor therapy - docetaxel (Taxotere®) - in patients withadvanced cancer.Two parallel Phase I studies1) were performed, one monotherapy study(including 39 patients with non-small cell lung cancer (NSCLC),pancreatic cancer (PC) or renal cell cancer (RCC)) with ANYARA andone study in combination with docetaxel (13 patients with NSCLC), inorder to assess the safety, tolerability and pharmacology of ANYARA.The results showed that ANYARA was well tolerated both as monotherapyand in combination with docetaxel.ANYARA showed immunological activity including systemic increase ininflammatory cytokines, selective expansion of ANYARA reactiveT-cells and induction of tumor infiltrating T-cells. Anti-tumoractivity was assessed and in the mono study fourteen patients (36%)had Stable Disease (SD) after two months. In the combo study the bestoverall response was confirmed Partial Response (a tumor reduction ofat least 30 percent), for 2 patients (15%) and SD for 5 patients(38%).ANYARA is presently in development primarily for the treatment ofrenal cell cancer. A pivotal phase III study, which has completedenrollment of over 500 patients, is currently ongoing.Active Biotech AB (publ)Tomas LeandersonPresident & CEO1) Previously presented in summary in press releases: December 13,2006 "Active Biotech's Novel Cancer Treatment ANYARA ShowsPharmacological Proof of Concept after Successful Phase I Studies"and October 24, 2007 "Active Biotech's Cancer Project ANYARA ProvenSafe in Combination with Taxotere®", now detailed in JCO.For further information, please contactTomas Leanderson, President & CEOTel: +46 46 19 20 95tomas.leanderson(at)activebiotech.comGöran Forsberg, VP IR & Business DevelopmentTel: +46 46 19 11 54goran.forsberg(at)activebiotech.comNotes to editorsAbout ANYARAANYARA is a TTS (Tumor Targeting Superantigens) compound that makesthe treatment of cancer tumor-specific. The development of ANYARA ismainly focused on renal cell cancer. Positive data was reported inconnection with the interim analysis in Phase II/III and fromclinical Phase I trials in lung cancer, renal cell cancer andpancreatic cancer. The median survival of 26.2 months observed forpatients with advanced renal cancer and treated with ANYARA is twicethe expected length. ANYARA has been granted orphan-drug status bythe EMEA for the indication renal cancer. Information concerning theongoing clinical trial is available at www.activebiotech.com andwww.clinicaltrials.gov.About Active BiotechActive Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnologycompany with focus on autoimmune/inflammatory diseases and cancer.Projects in pivotal phase are laquinimod, an orally administeredsmall molecule with unique immunomodulatory properties for thetreatment of multiple sclerosis, as well as ANYARA for use in cancertargeted therapy, primarily of renal cancer. Further key projects inclinical development comprise the three orally administered compoundsTASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Pleasevisit www.activebiotech.com for more information.Active Biotech ABPO Box 724, SE-220 07 LundSwedenTel: +46 (0)46-19 20 00Fax: +46 (0)46-19 11 00Active Biotech is required under the Securities Markets Act to makethe information in this press release public. The information wassubmitted for publication at 08:30 am CET on July 28, 2009.This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 28.07.2009 - 08:30 Uhr
Sprache: Deutsch
News-ID 4025
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 274 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Active Biotech's Cancer Project ANYARA Featured in Journal of
Clinical Oncology"
steht unter der journalistisch-redaktionellen Verantwortung von
Active Biotech (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
